GLP-1s

Eli Lilly has launched a multidose version of its blockbuster weight loss drug Zepbound that gives patients a month’s worth of treatment in a single injection pen.   On Feb. 23, the drugmaker said the FDA approved a label expansion for…

Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with plaque psoriasis and obesity or overweight. At 36 weeks, 27.1% of patients receiving both drugs…

In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of chronic kidney disease and acute kidney injury.  The study, published Jan. 20 in JAMA, analyzed the comparative effectiveness of both…

Telehealth company eMed has partnered with CVS Caremark to offer a GLP-1 benefit model that lets employers subsidize weight loss medications without covering the full cost, Axios reported Feb. 16.  The arrangement allows eligible employees to purchase GLP-1s online through…

GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market. Here are three trends driving the drug class forward: 1. Regulatory momentum accelerates On Jan. 13, the FDA directed…

Patients with endometrial hyperplasia or benign uterine pathology had a 66% reduced risk of developing endometrial cancer when treated with progestins and a GLP-1 compared to patients treated with progestins alone, according to a study published Feb. 10 in JAMA…

Two days after offering compounded versions of oral Wegovy, telehealth company Hims & Hers pulled the product from its platform amid pressure from HHS and Novo Nordisk.  On Feb. 5, Hims & Hers began selling compounded formulations of Novo Nordisk’s…

Relations among brand-name GLP-1 manufacturers and compounding pharmacies are deteriorating as weight loss pills enter the U.S. market and competition intensifies. Hims & Hers, a telehealth company that sells medications for erectile dysfunction, hair loss, birth control and weight loss,…

Novo Nordisk’s oral version of Wegovy may be the fastest drug launch in U.S. history. In its third week on the market, the once-daily GLP-1 recorded 26,100 prescriptions, a 42% increase week over week. Early prescription volume has also outpaced…

Novo Nordisk has appointed Jamey Millar, former CEO of Optum Specialty Holdings, as the drug company’s executive vice president of U.S. operations, effective Feb. 5.  In the role, Mr. Millar will oversee Novo Nordisk’s largest sales region, according to Novo…